Rns out6 Sep 2021 13:57
BARDA approval of additional $18.8m funding
Funds will expand the DeepView training clinical study for burn wounds
Total funding commitments of c. $93m received from BARDA to date to support the development of Spectral MD's artificial intelligence and multi-spectral imaging for wound healing assessment
LONDON, U.K. AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the commitment of additional funding of $18.8 million from the US Biomedical Advanced Research and Development Authority (BARDA), which will be used to expand the current clinical training study of Spectral MD's DeepView® Wound Imaging System for burn wound healing assessment.